A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure

Chest

Volumn 120, Issue 2, 2001, Pages 460-466

  Torre Amione, Guillermo ^a   Durand, Jean Bernard ^a   Nagueh, Sheriff ^a   Vooletich, Mary T ^a   Kobrin, Isaac ^b   Pratt, Craig ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Endothelins; Heart failure; Pharmacologic therapy

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; NITRATE; TEZOSENTAN; UNCLASSIFIED DRUG; VASODILATOR AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG CAPILLARY PRESSURE; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TREATMENT OUTCOME; VASODILATATION;

EID: 0034825957     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.2.460     Document Type: Article

References (23)

1. Heart Failure Society of America (HFSA) practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction; pharmacologic approaches
2. Heart failure: Evaluation and treatment of patients with left ventricular systolic dysfunction
3. Inotropic therapy for heart failure
4. Newer drug therapy for congestive heart failure
5. Hypotension with dobutamine: β-adrenergic antagonist selectivity at low doses of carvedilol
6. Factors causing arrhythmias in chronic congestive heart failure
7. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure
8. Endothelin in chronic heart failure: Current position and future prospects
9. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction
10. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology
11. Endothelin receptors in cultured adult rat cardiac fibroblasts
12. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
13. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
14. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
15. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use
16. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure
17. Dose dependency of hemodynamic changes to the endothelin-receptor antagonist tezosentan in patients with heart failure
18. Cardiac mechanics during development of heart failure: SOLVD Investigators
19. Diastolic failure: Pathophysiology and therapeutic implications
20. Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function
21. Congestive heart failure and the role of two-dimensional Doppler echocardiography: A primer for cardiac sonographers
22. Noninvasive evaluation of hemodynamics by Doppler echocardiography
23. Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy: An ominous prognostic sign